NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-31
Reading HIMS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue reaches $2.8-$3.0 billion in 2026: revenue guidance $2.8-$3.0 billion vs $2.8 billion target FY26.
View ThesisRevenue is growing steadily — about 33% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 4% on a typical day and fell roughly 78% in its worst 12-month stretch.
View RiskHIMS must improve revenue to justify its current price. Revenue guidance is $2.8-$3.0 billion for 2026, but the last quarter missed expectations. It trades at 45× P/E, which is above the 22× peer median. This suggests the market expects strong growth, but the recent earnings miss raises concerns. If HIMS cuts guidance, it could face further pressure. Peer multiples imply a price about 34% below where it trades; this read is provisional.
Trailing returns as of 2026-07-31. HIMS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering HIMS (as of Jul 2026).
Based on 6 Wall Street analysts offering 12-month price targets for HIMS in the last 4 months.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Advances: Focus on revenue growth
GLP-1 growth signals potential revenue increase.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $27.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $27.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Focus on revenue growth
Concerns about growth potential may hinder revenue.
